Zynex Executives Recognized Among Top 25 in Medical Technology


ENGLEWOOD, Colo., May 7, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today is proud to announce that two of our executives have been featured among Medical Technology's Top 25 by The Healthcare Technology Report. This prestigious recognition highlights the quality and depth of talent within Zynex.

Zynex

Anna Lucsok, Chief Operating Officer, and Steve Fox, Vice President of Sales, are recognized for their remarkable achievements and expertise in the field. Individuals selected for the recognition have demonstrated exceptional skills in managing product portfolios and leading departments.

"We're pleased to have our team members included in the Top 25 Medical Device Executives for 2024," said Thomas Sandgaard, CEO of Zynex. "The Healthcare Technology Report's rankings include peers from some of the largest and most innovative companies in the medical device space. We are proud to have our team included amongst our distinguished peers and believe these rankings indicate the great breadth and depth of talent we are building and our commitment to fostering a culture of excellence."

About The Healthcare Technology Report 

The Healthcare Technology Report (HLTR) provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector. 

About Zynex

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

Investor Relations Contact:
Quinn Callanan, CFA or Brian Prenoveau, CFA
MZ Group – MZ North America
ZYXI@mzgroup.us
+949 694 9594

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zynex-executives-recognized-among-top-25-in-medical-technology-302138074.html

SOURCE Zynex

Werbung

Zynex Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Zynex nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
10.03.08 Zynex Medical einen Fuß in die Tür stellen Global Biotech Investing

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.